Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Study of IgG Fc Glycan Composition in Human Immunity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female 18-80 years of age~* Healthy volunteers without significant medical problems~* Able to give informed consent to participate~* Willing to receive a single dose of an FDA-approved vaccine (either the influenza virus, pneumococcal or meningococcal vaccine)~* Documented previous infection with dengue, zika or chikungunya virus or no history of dengue, zika or chikungunya infection.~Exclusion Criteria:~* Prior allergic reaction to commercial vaccination~* For Flumist participants: Close contact with person with severely compromised immune system requiring isolation~* For Flumist participants: Current illness that limits delivery to nasal airway (mild illness, such as diarrhea or mild respiratory infection with or without fever, and local infections do not apply)~* History of seizure disorder for Flumist group participants only.~* Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study.~* Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation.~* In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol.~* Currently taking systemic steroids or other immunomodulatory medications including anticancer medications and antiviral medications.~* Egg allergy~* Received the influenza vaccine less than 1 month ago and/or received the pneumococcal and meningococcal vaccine less than 4 years ago~* Confirmed HIV infection, positive for hepatitis B surface antigen or positive for hepatitis C antibodies.~* Is pregnant or lactating~* History of Guillain-Barre syndrome~* Poor venous access~* Unable to continue participation for 12 weeks~* Any clinically significant abnormality on medical history or physical examination including history of immunodeficiency or autoimmune disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Biologic/Vaccine, Age 18-64 cohort (Type: ACTIVE_COMPARATOR): Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
- Biologic/Vaccine, Age 65-80 cohort (Type: ACTIVE_COMPARATOR): Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
- Vaccine, healthy adults (Type: ACTIVE_COMPARATOR): Vaccination. IM Pneumococcal, meningococcal, or flu vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).